IMPROVE-IT (TIMI 40) determined whether the addition of ezetimibe to statin therapy, using ezetimibe/simvastatin, improves cardiovascular outcomes compared with simvastatin monotherapy in patients after ACS. In addition, the difference in achieved LDL-C levels between the groups provided data on whether the target for LDL-C lowering should be reduced further.
MAIN RESULTS:
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
N Engl J Med. 2015 Jun 18;372(25):2387-97.
MAIN RESULTS PRESENTATION
PRESENTATIONS
On-Treatment Analysis (AHA 2014)
Total Events (Murphy, ACC 2015)
hsTnt (Qamar, AHA 2017)
Biomarkers (Qamar, AHA 2017)
Association of Genetic Risk Score with Risk of Recurrent Coronary Events in IMPROVE-IT (Ruff AHA 2018)